CN113968845A - AZD 9291-gallate and preparation method thereof - Google Patents

AZD 9291-gallate and preparation method thereof Download PDF

Info

Publication number
CN113968845A
CN113968845A CN202010725147.2A CN202010725147A CN113968845A CN 113968845 A CN113968845 A CN 113968845A CN 202010725147 A CN202010725147 A CN 202010725147A CN 113968845 A CN113968845 A CN 113968845A
Authority
CN
China
Prior art keywords
degrees
azd
gallate
azd9291
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010725147.2A
Other languages
Chinese (zh)
Inventor
王聚聚
翟立海
夏祥来
汪慧岩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lunan Pharmaceutical Group Corp
Original Assignee
Lunan Pharmaceutical Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunan Pharmaceutical Group Corp filed Critical Lunan Pharmaceutical Group Corp
Priority to CN202010725147.2A priority Critical patent/CN113968845A/en
Publication of CN113968845A publication Critical patent/CN113968845A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the technical field of crystal form drug molecules, and particularly provides AZD 9291-gallate and a preparation method and application thereof, wherein the AZD 9291-gallate uses Cu-Kalpha radiation, and an X-ray diffraction spectrogram expressed by 2 theta has characteristic peaks at 5.38 +/-0.2 degrees, 8.39 +/-0.2 degrees, 10.96 +/-0.2 degrees, 13.91 +/-0.2 degrees, 15.46 +/-0.2 degrees, 17.32 +/-0.2 degrees, 17.62 +/-0.2 degrees and 24.42 +/-0.2 degrees.

Description

AZD 9291-gallate and preparation method thereof
Technical Field
The invention relates to the technical field of crystal form drug molecules, in particular to the technical field of AZD9291 crystal forms, and specifically relates to AZD9291 gallate and a preparation method and application thereof.
Background
AZD9291(Osimertinib), chemical name: n- [2- [ [2- (dimethylamino) ethyl ] (methyl) amino ] -4-methoxy-5- [ [4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl ] amino ] phenyl ] prop-2-enamide, english name: n- (2- { [2- (dimethyl amino) ethyl ] (methyl) amino } -4-methoxy-5- { [4- (1-methyl-1H)
-indol-3-yl)-2-pyrimidinyl]amino } phenyl) acrylamide. CAS number:1421373-65- 0the structural formula is shown as follows:
Figure BDA0002601392080000011
if the lung cancer patient has EGFR or ALK gene mutation, the targeted drug can obtain better survival benefit. However, the efficacy of these drugs is generally short-lived, and resistance occurs in months 9-11, which arises because cancer cells can evade the therapeutic activity of EGFR or ALK inhibitors by mutating and changing the growth pattern.
ADZ9291, developed by AstraZeneca (AstraZeneca), is a third generation oral, irreversible selective EGFR mutation inhibitor useful for activating and resistant mutant EGFR, i.e., 50% of acquired resistance to EGFR treatment for advanced non-small cell lung cancer patients is caused by the T790M mutation, and ADZ9291 can nullify this challenging mutation. ADZ9291 has better treatment effect on NSCLC patients with existing resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and T790M mutation.
Patent CN103702990A discloses the structure of ADZ9291 compound. Polymorphic forms of this compound and its mesylate salt are also disclosed in this patent, including form B of the ADZ9291 mesylate salt form A, ADZ9291 mesylate salt. Patent CN104961731A discloses ADZ9291 phosphate; patent CN106432231A discloses ADZ9291 pharmaceutically acceptable salts sulfate, p-toluenesulfonate, tartrate, acetate and citrate; patent CN107915725A patent discloses novel pharmaceutically acceptable salts of maleic acid, fumaric acid, gluconic acid, malonic acid, succinic acid and lactic acid.
The former company used the mesylate salt of AZD9291 for clinical studies. However, methanesulfonic acid is highly toxic and, in selective cases, unsuitable for pharmaceutical use. And the methanesulfonate has problems of high hygroscopicity and deliquescence due to high humidity. Therefore, it is necessary to develop other salts with high bioavailability, low toxicity and suitability for pharmaceutical use. Although the prior literature has disclosed numerous AZD9291 crystal forms, systematic studies on the crystal forms are still to be perfected.
Disclosure of Invention
The invention provides AZD 9291-gallate with high solubility and good stability and a preparation method thereof, and the medicinal salt is beneficial to patent medicine and enables AZD9291 to better exert the drug effect.
The specific technical content of the invention is as follows:
an AZD 9291-gallate, Cu-Kalpha radiation is used, X-ray diffraction spectrum expressed by 2 theta has characteristic peaks at 5.38 + -0.2 deg., 8.39 + -0.2 deg., 10.96 + -0.2 deg., 13.91 + -0.2 deg., 15.46 + -0.2 deg., 17.32 + -0.2 deg., 17.62 + -0.2 deg., and 24.42 + -0.2 deg.
Preferably, the AZD 9291-gallate has characteristic peaks at 5.38 +/-0.2 °, 8.39 +/-0.2 °, 10.96 +/-0.2 °, 12.02 +/-0.2 °, 13.91 +/-0.2 °, 14.31 +/-0.2 °, 15.46 +/-0.2 °, 16.66 +/-0.2 °, 17.32 +/-0.2 °, 17.62 +/-0.2 °, 20.14 +/-0.2 °, 21.20 +/-0.2 °, 21.42 +/-0.2 °, 22.82 +/-0.2 °, 23.27 +/-0.2 °, 24.42 +/-0.2 ° and 25.78 +/-0.2 ° in an X-ray diffraction spectrum expressed by 2 theta using Cu-Kalpha radiation.
Further preferably, the AZD 9291-gallate has an X-ray diffraction pattern, expressed in 2 Θ using Cu-ka radiation, characterized peaks at 5.38 ± 0.2 °, 8.39 ± 0.2 °, 10.96 ± 0.2 °, 12.02 ± 0.2 °, 13.91 ± 0.2 °, 14.31 ± 0.2 °, 15.46 ± 0.2 °, 16.66 ± 0.2 °, 17.32 ± 0.2 °, 17.62 ± 0.2 °, 18.01 ± 0.2 °, 18.34 ± 0.2 °, 20.14 ± 0.2 °, 21.20 ± 0.2 °, 21.42 ± 0.2 °, 22.33 ± 0.2 °, 22.82 ± 0.2 °, 23.27 ± 0.2 °, 24.42 ± 0.2 °, 25.78 ± 0.2 °, 27.95 ± 0.2 °, 28.75 ± 0.2 °, 29.15 ± 0.2 °.
Preferably, the AZD 9291-gallate has an X-ray diffraction pattern as shown in figure 1, using Cu-K alpha radiation.
A process for the preparation of the AZD 9291-gallate, comprising the steps of:
dissolving AZD9291 and gallic acid in a mixed solvent of an organic solvent and purified water, heating for dissolving, cooling for crystallization after the solution is clarified, filtering and drying to obtain the product.
The organic solvent is selected from one or more mixed solvents of acetone, methanol, ethanol and acetonitrile.
Preferably, the organic solvent is one or two of acetone and methanol.
The molar ratio of the AZD9291 to the gallic acid is 1: 1-1.1; preferably, the molar ratio of the AZD9291 to the gallic acid is 1: 1-1.05.
The mass-volume ratio of the AZD9291 to the organic solvent in the system is 10-25: 1, wherein the mass is in mg and the volume is in mL.
The volume ratio of the organic solvent to the purified water is 12-18: 1.
The temperature for dissolving and heating is 40-60 ℃.
The cooling crystallization temperature is 0-30 ℃, and preferably, the cooling crystallization temperature is 5-20 ℃.
The crystallization time is 45-72 hours.
The drying temperature is 45-70 ℃, and the drying time is 8-12 hours.
Confirmation of AZD 9291-gallate crystal structure
The X-ray crystal data of the invention is collected on a Japan science XtaLAB Synergy model instrument, the temperature is measured at 293(2) K, CuKa radiation is used, and data is collected in an omega scanning mode and Lp correction is carried out. Analyzing the structure by a direct method, finding out all non-hydrogen atoms by a difference Fourier method, obtaining all hydrogen atoms on carbon and nitrogen by theoretical hydrogenation, and refining the structure by a least square method.
The X-ray powder diffraction test instrument and the test conditions of the invention are as follows: PANALYTIC EMPyrean X-ray powder diffractometer; light source Cu target, flat sample stage, incident light path: BBHD, diffraction path: PIXCEL, voltage 45KV, current 40mA, divergence slit 1/4 degrees, anti-divergence slit 1 degree, cable-stayed slit 0.04rad degree, counting time of each step 0.5s, and scanning range 3-50 degrees.
The TGA/DSC thermal analysis tester and the test conditions in the invention are as follows: TGA/DSC thermogram METTLER TOLEDO TGA/DSC3 +; dynamic temperature section: 30-300 ℃; heating rate: 10 ℃/min; segment gas N2(ii) a Gas flow rate: 50 mL/min; crucible: aluminiumCrucible 40. mu.l.
The crystallography data of the AZD 9291-gallate prepared by the invention are tested and analyzed (see Table 1), and the crystallography parameters are as follows: monoclinic system, chiral space group P21C; the unit cell parameters are:
Figure BDA0002601392080000031
Figure BDA0002601392080000032
α is 90.00 °, β is 112.5079(15 °), γ is 90.00 °, unit cell volume
Figure BDA0002601392080000033
The molecular formula is: c35H41N7O8The molecular weight is: 687.75. the structural analysis photograph of the AZD 9291-gallate of the invention shows that the crystal has one molecule of AZD9291, one molecule of gallic acid and one molecule of water, as shown in figure 3. The stack diagram of AZD 9291-gallate of the invention is shown in figure 2.
TABLE 1 AZD 9291-gallate Primary crystallography data
Figure BDA0002601392080000034
Figure BDA0002601392080000041
According to the crystallography data, the characteristic peak in the X-ray powder diffraction pattern (Cu-K alpha) corresponding to the AZD 9291-gallate is detailed in attached figure 1 and table 2.
TABLE 2 AZD 9291-gallate major PXRD peaks
Figure BDA0002601392080000042
Figure BDA0002601392080000051
Figure BDA0002601392080000061
The result of the Differential Scanning Calorimetry (DSC) curve of the AZD 9291-gallate prepared by the invention is shown in figure 4, and the Differential Scanning Calorimetry (DSC) curve has an endothermic peak of 181.69 ℃; the thermogravimetric analysis (TGA) of the product has only one weight loss step, which indicates that the AZD 9291-gallate structure is stable. The AZD 9291-gallate has a DSC/TGA pattern shown in figure 4.
All AZD 9291-gallate samples prepared by the invention have the same crystallographic parameters, X-ray powder diffraction spectrogram and TGA/DSC thermogram.
The invention also provides a pharmaceutical composition which comprises the AZD 9291-gallate prepared above and other active ingredients and/or pharmaceutically acceptable auxiliary ingredients which can be used in combination.
Preferably, the pharmaceutical composition can be prepared into spray, tablets, capsules, powder injections, liquid injections and the like by using standard or conventional technology.
The invention also provides application of the AZD 9291-gallic acid salt in preparing a medicament for treating lung cancer, in particular application in preparing a medicament for treating non-small cell lung cancer.
Compared with the prior art, the AZD 9291-gallate prepared by the invention has the advantages of obviously improved solubility and good stability, and is suitable for being prepared into medicaments.
Drawings
FIG. 1 is an X-ray powder diffraction pattern of AZD 9291-gallate;
FIG. 2 is a stacking diagram of AZD 9291-gallate;
FIG. 3 is an ORTEP diagram of AZD 9291-gallate;
FIG. 4 is a TGA/DSC thermogram of AZD 9291-gallate.
Detailed Description
The invention is further illustrated by the following examples, which should be properly understood: the examples of the present invention are intended to be illustrative only and not to be limiting, and therefore, the present invention is intended to be simply modified within the scope of the present invention as claimed.
Example 1
Adding 2.0g of AZD9291 and 0.72g of gallic acid into a mixed solvent of 100mL of methanol and 7mL of purified water, heating to 55 ℃, stirring for dissolving, carrying out reflux reaction for 1 hour, slowly cooling to 15 ℃, standing at a controlled temperature for 50 hours for crystallization, filtering, washing a filter cake with methanol, and carrying out vacuum drying at 50 ℃ for 10 hours to obtain AZD 9291-gallate, wherein the yield is 97.68% and the purity is 99.97%.
Example 2
Adding 2.0g of AZD9291 and 0.70g of gallic acid into a mixed solvent of 60mL of methanol, 70mL of acetonitrile and 8mL of purified water, heating to 50 ℃, stirring for dissolving, carrying out reflux reaction for 1 hour, slowly cooling to 20 ℃, standing at a controlled temperature for crystallization for 65 hours, filtering, washing a filter cake with methanol, and carrying out vacuum drying at 60 ℃ for 8 hours to obtain AZD 9291-gallate, wherein the yield is 96.67 percent, and the purity is 99.97 percent.
Example 3
Adding 2.0g of AZD9291 and 0.75g of gallic acid into a mixed solvent of 80ml of ethanol and 6ml of purified water, heating to 45 ℃, stirring for dissolving, carrying out reflux reaction for 1 hour, slowly cooling to 10 ℃, standing at a controlled temperature for crystallization for 60 hours, filtering, washing a filter cake with ethanol, and carrying out vacuum drying at 70 ℃ for 9 hours to obtain AZD 9291-gallate, wherein the yield is 93.33 percent and the purity is 99.96 percent.
Example 4
Adding 2.0g of AZD9291 and 0.68g of gallic acid into a mixed solvent of 200ml of acetone and 16ml of purified water, heating to 55 ℃, stirring for dissolving, carrying out reflux reaction for 1 hour, slowly cooling to 30 ℃, standing at a controlled temperature for crystallization for 72 hours, filtering, washing a filter cake with acetone, and carrying out vacuum drying at 45 ℃ for 12 hours to obtain AZD 9291-gallate, wherein the yield is 85.77 percent, and the purity is 99.95 percent.
Example 5
Adding 2.0g of AZD9291 and 1.02g of gallic acid into a mixed solvent of 100ml of acetone and 6ml of purified water, heating to 40 ℃, stirring for dissolving, carrying out reflux reaction for 1 hour, slowly cooling to 0 ℃, standing at a controlled temperature for crystallization for 45 hours, filtering, washing a filter cake with acetone, and carrying out vacuum drying at 60 ℃ for 9 hours to obtain AZD 9291-gallate, wherein the yield is 88.20 percent, and the purity is 99.94 percent.
Verification test
(1) Stability test
The stability test was carried out on the AZD 9291-gallate prepared in examples 1-5 of the invention. The specific stability test method is carried out according to the guidance method of stability investigation in the fourth part of the Chinese pharmacopoeia 2015 edition, the purity is detected by an HPLC method, and the specific test results are shown in Table 3.
TABLE 3 stability test results of AZD 9291-gallate under light, high temperature and high humidity conditions
Figure BDA0002601392080000071
Figure BDA0002601392080000081
As can be seen from Table 3, the purity of the AZD 9291-gallate prepared in the embodiments 1-5 of the present invention does not change significantly under the conditions of illumination, high temperature and high humidity, and it can be seen that the AZD 9291-gallate prepared in the present invention has good stability and is beneficial to storage.
(2) Solubility test
The solubility comparison study is carried out on the AZD 9291-gallate prepared in the embodiments 1-5 and the AZD9291 mesylate crystal form A, AZD9291 fumarate in the prior art. The method comprises the following steps: respectively measuring 10ml of medium (water, 0.1mol/LHCl solution and phosphate buffer solution with pH of 6.8) into a penicillin bottle, adding excessive samples to be detected, sealing the penicillin bottle, placing the penicillin bottle in a constant-temperature water bath at 25 ℃, stirring for 1 hour, filtering through a 0.45-micron filter membrane, and taking filtrate; the absorbance was measured at a wavelength of 210nm, and the solubility was calculated by measuring the absorbance of a standard control.
TABLE 4 solubility (mg/ml) of AZD 9291-gallate in different media
Figure BDA0002601392080000082
The test data show that compared with the AZD9291 mesylate crystal form A, AZD9291 fumarate in the prior art, the AZD 9291-gallate prepared in the embodiments 1-5 of the invention has obviously improved solubility in water and phosphoric acid medium, which indicates that the AZD 9291-gallate prepared in the invention has good solubility and can be prepared into a pharmaceutical preparation which is beneficial to absorption by human body.

Claims (10)

1. An AZD 9291-gallate, which is characterized in that: an X-ray diffraction spectrum expressed by 2 theta by using Cu-Kalpha radiation has characteristic peaks at 5.38 +/-0.2 degrees, 8.39 +/-0.2 degrees, 10.96 +/-0.2 degrees, 13.91 +/-0.2 degrees, 15.46 +/-0.2 degrees, 17.32 +/-0.2 degrees, 17.62 +/-0.2 degrees and 24.42 +/-0.2 degrees.
2. AZD 9291-gallate according to claim 1, wherein: an X-ray diffraction spectrum expressed by 2 theta by using Cu-Kalpha radiation has characteristic peaks at 5.38 +/-0.2 degrees, 8.39 +/-0.2 degrees, 10.96 +/-0.2 degrees, 12.02 +/-0.2 degrees, 13.91 +/-0.2 degrees, 14.31 +/-0.2 degrees, 15.46 +/-0.2 degrees, 16.66 +/-0.2 degrees, 17.32 +/-0.2 degrees, 17.62 +/-0.2 degrees, 20.14 +/-0.2 degrees, 21.20 +/-0.2 degrees, 21.42 +/-0.2 degrees, 22.82 +/-0.2 degrees, 23.27 +/-0.2 degrees, 24.42 +/-0.2 degrees and 25.78 +/-0.2 degrees.
3. AZD 9291-gallate according to claim 1, wherein: the AZD 9291-gallate has characteristic peaks at 5.38 +/-0.2 degrees, 8.39 +/-0.2 degrees, 10.96 +/-0.2 degrees, 12.02 +/-0.2 degrees, 13.91 +/-0.2 degrees, 14.31 +/-0.2 degrees, 15.46 +/-0.2 degrees, 16.66 +/-0.2 degrees, 17.32 +/-0.2 degrees, 17.62 +/-0.2 degrees, 18.01 +/-0.2 degrees, 18.34 +/-0.2 degrees, 20.14 +/-0.2 degrees, 21.20 +/-0.2 degrees, 21.42 +/-0.2 degrees, 22.33 +/-0.2 degrees, 22.82 +/-0.2 degrees, 23.27 +/-0.2 degrees, 24.42 +/-0.2 degrees, 25.78 +/-0.2 degrees, 27.95 +/-0.2 degrees, 28.75 +/-0.2 degrees, 29.15 +/-0.2 degrees by using Cu-Kalpha radiation and an X-ray diffraction spectrum expressed by 2 theta.
4. AZD 9291-gallate according to claim 1, wherein: the AZD 9291-gallate has an X-ray diffraction pattern shown in figure 1 by using Cu-K alpha radiation.
5. A process for the preparation of AZD 9291-gallate as claimed in any one of the claims 1 to 4, comprising the steps of:
dissolving AZD9291 and gallic acid in a mixed solvent of an organic solvent and purified water, heating for dissolving, cooling for crystallization after the solution is clarified, filtering and drying to obtain the product.
6. The method of claim 5, wherein: the organic solvent is selected from one or more mixed solvents of acetone, methanol, ethanol and acetonitrile.
7. The method of claim 5, wherein: the molar ratio of the AZD9291 to the gallic acid is 1: 1-1.1.
8. The method of claim 5, wherein: the mass-volume ratio of the AZD9291 to the organic solvent in the system is 10-25: 1, wherein the mass is in mg and the volume is in mL.
9. The method of claim 5, wherein: the volume ratio of the organic solvent to the purified water is 12-18: 1.
10. Use of an AZD 9291-gallate as claimed in any one of claims 1 to 4 in the manufacture of a medicament for the treatment of lung cancer.
CN202010725147.2A 2020-07-24 2020-07-24 AZD 9291-gallate and preparation method thereof Pending CN113968845A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010725147.2A CN113968845A (en) 2020-07-24 2020-07-24 AZD 9291-gallate and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010725147.2A CN113968845A (en) 2020-07-24 2020-07-24 AZD 9291-gallate and preparation method thereof

Publications (1)

Publication Number Publication Date
CN113968845A true CN113968845A (en) 2022-01-25

Family

ID=79585751

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010725147.2A Pending CN113968845A (en) 2020-07-24 2020-07-24 AZD 9291-gallate and preparation method thereof

Country Status (1)

Country Link
CN (1) CN113968845A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023098848A1 (en) * 2021-12-03 2023-06-08 湖南湘源美东医药科技有限公司 Osimertinib co-crystal, preparation method, and application as drug or in pharmaceutical formulation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702990A (en) * 2011-07-27 2014-04-02 阿斯利康(瑞典)有限公司 2-(2,4,5-substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
CN104961731A (en) * 2015-02-05 2015-10-07 苏州晶云药物科技有限公司 Phosphate of epidermal growth factor receptor inhibitor, and crystal form and preparation method thereof
CN106432231A (en) * 2016-09-09 2017-02-22 无锡佰翱得生物科学有限公司 AZD 9291 pharmaceutical salt and crystal form and preparation method thereof
CN106674202A (en) * 2015-11-05 2017-05-17 惠州信立泰药业有限公司 Dimethyl sulfonate of compound A, crystal form of dimethyl sulfonate, and medicinal composition containing dimethyl sulfonate
CN107176954A (en) * 2017-06-02 2017-09-19 无锡双良生物科技有限公司 Pharmaceutical salts and its crystal formation, the preparation method and application of a kind of EGFR inhibitor
CN107915725A (en) * 2017-10-20 2018-04-17 复旦大学 Pharmaceutical salts of AZD9291 and preparation method thereof
CN108558835A (en) * 2017-05-24 2018-09-21 浙江同源康医药股份有限公司 A kind of crystal form, the Preparation method and use of deuterated AZD9291
CN110483486A (en) * 2019-09-17 2019-11-22 鲁南制药集团股份有限公司 A kind of western Tenylidone of Austria coughs up hydrochlorate crystal form and preparation method thereof
CN111303124A (en) * 2020-04-08 2020-06-19 北京赛思源生物医药技术有限公司 Novel crystal of oxitinib mesylate

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702990A (en) * 2011-07-27 2014-04-02 阿斯利康(瑞典)有限公司 2-(2,4,5-substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
CN104961731A (en) * 2015-02-05 2015-10-07 苏州晶云药物科技有限公司 Phosphate of epidermal growth factor receptor inhibitor, and crystal form and preparation method thereof
CN106674202A (en) * 2015-11-05 2017-05-17 惠州信立泰药业有限公司 Dimethyl sulfonate of compound A, crystal form of dimethyl sulfonate, and medicinal composition containing dimethyl sulfonate
CN106432231A (en) * 2016-09-09 2017-02-22 无锡佰翱得生物科学有限公司 AZD 9291 pharmaceutical salt and crystal form and preparation method thereof
CN108558835A (en) * 2017-05-24 2018-09-21 浙江同源康医药股份有限公司 A kind of crystal form, the Preparation method and use of deuterated AZD9291
CN107176954A (en) * 2017-06-02 2017-09-19 无锡双良生物科技有限公司 Pharmaceutical salts and its crystal formation, the preparation method and application of a kind of EGFR inhibitor
CN107915725A (en) * 2017-10-20 2018-04-17 复旦大学 Pharmaceutical salts of AZD9291 and preparation method thereof
CN110483486A (en) * 2019-09-17 2019-11-22 鲁南制药集团股份有限公司 A kind of western Tenylidone of Austria coughs up hydrochlorate crystal form and preparation method thereof
CN111303124A (en) * 2020-04-08 2020-06-19 北京赛思源生物医药技术有限公司 Novel crystal of oxitinib mesylate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023098848A1 (en) * 2021-12-03 2023-06-08 湖南湘源美东医药科技有限公司 Osimertinib co-crystal, preparation method, and application as drug or in pharmaceutical formulation

Similar Documents

Publication Publication Date Title
AU2018275277B2 (en) Pharmaceutically acceptable salt of EGFR inhibitor, crystal form thereof, preparation method therefor and application thereof
WO2016124137A1 (en) Phosphate of epidermal growth factor receptor inhibitor, crystalline form of phosphate, and preparation method
RU2686722C1 (en) New crystals of uracil compound
CN110483486B (en) Crystal form of oxtinib ketorolac and preparation method thereof
US20160145241A1 (en) Stable crystal form of tipiracil hydrochloride and crystallization method for the same
CN112142679B (en) Gefitinib and vanilloid eutectic methanol solvate and preparation method thereof
US8946249B2 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
CN112047892A (en) Gefitinib and 3-hydroxybenzoic acid eutectic
WO2016136928A1 (en) Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal
CN112047893A (en) Gefitinib and salicylic acid cocrystal
AU2015342444B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
CN113968845A (en) AZD 9291-gallate and preparation method thereof
CN114685455A (en) AZD9291 crystalline solid
CN114075169A (en) Pharmaceutical cocrystal of oxitinib and preparation method thereof
US11192882B2 (en) Crystal form of small molecule immune compound, preparation method thereof and pharmaceutical composition containing the same
WO2023083356A1 (en) Nitrogen fused-heterocyclic amide compound in solid form and use thereof
CN114075170A (en) Oxitinib medicinal salt and preparation method thereof
CN116768856A (en) Salt of substituted amino six-membered nitrogen heterocyclic compound, crystal form, preparation method and application thereof
CN113372331B (en) Novel crystal form of Orientinib monohydrate
CN113929664A (en) AZD9291-3, 5-pyridine dicarboxylic acid salt and preparation method thereof
CN113929663A (en) AZD 9291-2-indole formate and preparation method thereof
CN113801101A (en) AZD 9291-2-ketoglutarate and preparation method thereof
CN114105957A (en) Oxitinib-terephthalic acid crystal and preparation method thereof
CN113754596A (en) Gefitinib co-crystal
US10544129B2 (en) Crystalline forms of AP26113, and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination